Additionally, cancer-specific loss of isozyme diversity, exemplified by lower GPAT2 RNA levels in TNBC than in GPAT148, suggests potential mitigation of LPA production upon SNRNP200 inhibition. The gene discussed is GPAT2; the disease is cancer.